Literature DB >> 32479977

One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study.

Hideaki Uchida1, Masahiro Kamata2, Aika Kato1, Itsumi Mizukawa1, Ayu Watanabe1, Ai Agematsu1, Mayumi Nagata1, Saki Fukaya1, Kotaro Hayashi1, Atsuko Fukuyasu1, Takamitsu Tanaka1, Takeko Ishikawa1, Takamitsu Ohnishi1, Yayoi Tada1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32479977     DOI： 10.1016/j.jaad.2020.05.102

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  7 in total

1.  The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.

Authors:  Y Zhao; L Wu; Q Lu; X Gao; X Zhu; X Yao; L Li; W Li; Y Ding; Z Song; L Liu; N Dang; C Zhang; X Liu; J Gu; J Wang; S Geng; Q Liu; Y Guo; L Dong; H Su; L Bai; J T O'Malley; J Luo; E Laws; L Mannent; M Ruddy; N Amin; A Bansal; T Ota; M Wang; J Zhang
Journal:  Br J Dermatol       Date:  2021-10-21       Impact factor: 11.113

2.  Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset.

Authors:  Lawrence F Eichenfield; April Armstrong; Emma Guttman-Yassky; Peter A Lio; Chi-Chang Chen; Dionne M Hines; Catherine B McGuiness; Sohini Ganguli; Dimittri Delevry; Debra Sierka; Usha G Mallya
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-11

3.  Rapid Enlargement of Vitiligo Vulgaris after Initiation of Dupilumab for Atopic Dermatitis: A Case Report.

Authors:  Shintaro Takeoka; Masahiro Kamata; Ikumi Yokoi; Aya Takehara; Yayoi Tada
Journal:  Acta Derm Venereol       Date:  2021-10-28       Impact factor: 3.875

Review 4.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

5.  Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea.

Authors:  Dong Hun Lee; Hyun Chang Ko; Chan Ho Na; Joo Young Roh; Kui Young Park; Young Lip Park; Young Min Park; Chang Ook Park; Chun Wook Park; Youin Bae; Young-Joon Seo; Sang Wook Son; Jiyoung Ahn; Hye Jung Jung; Jun-Mo Yang; Chong Hyun Won; Kwang Ho Yoo; Bark Lynn Lew; Sang Eun Lee; Sung Yul Lee; Seung-Chul Lee; Yang Won Lee; Ji Hyun Lee; Yong Hyun Jang; Jiehyun Jeon; Tae-Young Han; Sang Hyun Cho
Journal:  Ann Dermatol       Date:  2022-03-24       Impact factor: 1.444

6.  Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study.

Authors:  Bingjing Zhou; Cong Peng; Liqiao Li; Runqiu Liu; Lei Zhu; Xiang Chen; Jie Li
Journal:  Front Med (Lausanne)       Date:  2022-03-23

7.  A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world.

Authors:  Dong Hyek Jang; Seok Jae Heo; Hyung Don Kook; Dong Heon Lee; Hye Jung Jung; Mi Yeon Park; Jiyoung Ahn
Journal:  Sci Rep       Date:  2021-12-07       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.